NVS vs SYK
Novartis AG vs Stryker Corporation — AI-powered side-by-side comparison
VS
SYK
Stryker Corporation
70
Buy
| Metric | NVS | SYK |
|---|
| AI Score |
72
|
70
|
| Price |
$150.91
|
$338.83
|
| P/E Ratio |
22.85×
|
34.86×
|
| ROE |
30.5%
|
14.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
74.3%
|
65.2%
|
| Debt / Equity |
1.18×
|
0.62×
|
| Dividend Yield |
3.0%
|
1.0%
|
| RSI (14) |
32.8
|
49.4
|
| Beta |
0.462
|
0.771
|
| Expected Upside |
+3.5%
|
+10.4%
|
AI Committee View
Current Innellis committee reasoning for NVS versus SYK.
NVS leads by 2 points.
NVS scores 72/100 (Buy) versus SYK at 70/100 (Buy).
NVS Committee View
80% agreement
5 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- News sentiment is positive (+0.56 across 9 articles, 14d) — News
Bear Case
- MACD histogram negative -- bearish momentum — Technical
SYK Committee View
75% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- News sentiment is positive (+0.33 across 31 articles, 14d) — News
Bear Case
- MACD histogram negative -- bearish momentum — Technical